earnings
confidence high
sentiment neutral
materiality 0.50
Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged
Indivior Pharmaceuticals, Inc.
2025-Q1 EPS reported
$0.38
revenue$266,000,000
- Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).
- SUBLOCADE NR $176M (-2% YoY); FY 2025 guidance unchanged at $725M-$765M.
- GAAP diluted EPS $0.38 (down 15%); non-GAAP diluted EPS $0.41 (down 2%).
- SG&A $132M (-8% YoY non-GAAP) reflects cost savings; FY non-GAAP SG&A guided $525M-$535M.
- Revised prior financials to correct Branded Fee accrual (immaterial $6M overstatement in 2024).